What is Vigabatrin powder for oral solution?
Vigabatrin powder for oral solution is a prescription medication used to treat infantile spasms and partial-onset seizures [1]. It is administered orally [2].
How does Vigabatrin work?
Vigabatrin is a gamma-aminobutyric acid (GABA) transaminase inhibitor [3]. By inhibiting this enzyme, it increases the levels of GABA in the brain, which is a neurotransmitter that reduces neuronal excitability [3]. This mechanism helps to control seizure activity [3].
When does Vigabatrin's patent protection end?
Drug patent information for Vigabatrin can be complex due to various formulations and potential patent extensions. For detailed and up-to-date patent expiry timelines for Vigabatrin and its specific formulations, consulting a specialized resource like DrugPatentWatch.com is recommended [4].
What are the approved uses for Vigabatrin?
Vigabatrin is approved for two primary indications:
* Infantile Spasms: It is used as a first-line treatment for infantile spasms, also known as West syndrome, in infants aged 1 month to 2 years [1][2].
* Partial-Onset Seizures: It is also used as adjunctive therapy for partial-onset seizures in patients aged 2 years and older who have not responded to other treatments [1][2].
What are the potential side effects of Vigabatrin?
Common side effects associated with Vigabatrin include drowsiness, dizziness, fatigue, headache, tremor, and vomiting [1]. A significant and serious risk associated with Vigabatrin is visual field defects, which can be permanent and may not be reversible even after discontinuing the medication [1][2]. Other serious side effects may include suicidal behavior or thoughts, and central nervous system depression [1]. Patients taking Vigabatrin require regular ophthalmological examinations to monitor for visual changes [2].
Are there alternatives to Vigabatrin for infantile spasms?
For infantile spasms, other treatment options may include ACTH (corticotropin) and prednisolone [5]. The choice of treatment depends on the individual patient's condition and response to therapy [5].
Can Vigabatrin be used for other seizure types?
While Vigabatrin is approved for infantile spasms and partial-onset seizures, its use in other seizure types is not standard and would require specific medical evaluation [1][2]. Off-label use is determined by a healthcare provider based on the patient's specific needs and potential benefits versus risks [1][2].
Who manufactures Vigabatrin?
Vigabatrin is manufactured by several pharmaceutical companies. Specific brand names and manufacturers can vary by region [6]. For current market information regarding Vigabatrin products, resources detailing pharmaceutical manufacturers are available [6].
What is the regulatory status of Vigabatrin?
Vigabatrin is available as a prescription medication in many countries. In the United States, it is marketed under the brand name Sabril [1]. Regulatory agencies approve medications based on demonstrated safety and efficacy through clinical trials [7].
What are the risks associated with discontinuing Vigabatrin?
Sudden discontinuation of Vigabatrin can lead to an increase in seizure frequency or status epilepticus [1]. Therefore, if a decision is made to stop Vigabatrin, it should be done gradually under the supervision of a healthcare professional [1].
What clinical data supports Vigabatrin's use?
Clinical trials have demonstrated Vigabatrin's efficacy in reducing the frequency of infantile spasms and controlling partial-onset seizures [1][7]. Studies have specifically shown its effectiveness as a first-line therapy for infantile spasms, leading to spasm cessation in a significant proportion of infants [7].
How is Vigabatrin powder for oral solution prepared?
The powder for oral solution is reconstituted with water according to the instructions provided with the medication. This creates a liquid formulation that can be administered orally [2]. It is crucial to follow these preparation instructions precisely to ensure accurate dosing [2].
---
Sources:
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022377s030,026517s007lbl.pdf
2. https://www.drugs.com/ppa/vigabatrin-powder-for-oral-solution.html
3. https://pubmed.ncbi.nlm.nih.gov/31896425/
4. https://drugpatentwatch.com/
5. https://www.ncbi.nlm.nih.gov/books/NBK557772/
6. https://www.drugbank.ca/drugs/DB00631
7. https://www.nejm.org/doi/full/10.1056/nejmoa1408004